May 6, 2024- Teleflex Incorporated announced the presentation of multiple clinical studies at the 2024 American Urological Association Annual Meeting, which is being held in San Antonio, TX, from May 3 – 6, 2024. These studies add increased clinical evidence around the safety, efficacy and patient experience with a Prostatic Urethral Lift (PUL) using the UroLift™ System for benign BPH.
In addition to the presentation of clinical data, Teleflex will offer the first opportunity to view the UroLift™ 2 System with Advanced Tissue Control (ATC), which has recently received FDA clearance. The UroLift™ 2 ATC System offers physicians enhanced confidence, easier control of obstructive tissue, and targeting accuracy through tissue control wings and laser-etched needle markers designed to make tissue manipulation and implant delivery more precise.
BPH is a common condition in which the prostate enlarges as men get older. The enlarged prostate can press on and block the urethra, causing bothersome urinary symptoms.